Results 111 to 120 of about 56,276 (247)

Effect of anti-CD4 mAb induced by inhibiting B cell disorder on immune reconstruction of HIV-infected immunological non-responders. [PDF]

Mol Med
Ouyang Y, Wu K, Fu L, Yi P, Cheng D, Fu X.   +5 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

An Effective Prophylactic and Therapeutic Protection Against Botulinum Type A Intoxication in Mice and Rabbits Using a Humanized Monoclonal Antibody. [PDF]

Toxins (Basel)
Yu CH, Song YJ, Song DH, Joe HE, Kim CH, Yun H, Kim NY, Sim E, Jeong ST, Hur GH.   +9 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Successful targeting of multidrug-resistant tumors with bispecific antibodies. [PDF]

MAbs
Briante R, Zhai Q, Mohanty S, Zhang P, O'Connor A, Misker H, Wang W, Tan C, Abuhay M, Morgan J, Theolis R, Ponath P, Arathoon R.   +12 more
europepmc   +1 more source

Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab‐117 Against Human Tumors

Cancer Science, EarlyView.
A humanized cancer‐specific anti‐podoplanin monoclonal antibody humPMab‐117 exerts antibody‐dependent cellular cytotoxicity and complement‐dependent cytotoxicity against human tumor cells. In the xenograft tumor models, humPMab‐117 demonstrated strong antitumor efficacy.
Tomohiro Tanaka, Hiroyuki Suzuki, Tomokazu Ohishi, Manabu Kawada, Mika K. Kaneko, Yukinari Kato   +5 more
wiley   +1 more source

Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. [PDF]

Clin Exp Med
Soleimani Samarkhazan H, Noormohamadi H, Shafiei FS, Taghinejad Z, Maleknia M, Raoufi A, Nouri S, Mohammadi MH.   +7 more
europepmc   +1 more source

Does one model fit all mAbs? An evaluation of population pharmacokinetic models. [PDF]

MAbs
van den Berg SPH, Adolfsen PEA, Dorlo TPC, Rispens T.   +3 more
europepmc   +1 more source

Advancing Remission in Severe Asthma With Benralizumab: Latest Findings, Current Perspectives and Future Direction

Clinical &Experimental Allergy, EarlyView.
ABSTRACT The introduction of biologics, such as benralizumab (an anti‐IL‐5 receptor α humanised monoclonal antibody), has made remission a feasible goal for patients with severe eosinophilic asthma (SEA). However, there are remaining research gaps and no clear consensus on the definition of remission.
Renaud Louis, Marek Lommatzsch, David J. Jackson, Andrew Menzies‐Gow, Anat Shavit, David Cohen, Flavia C. L. Hoyte, Stephanie Korn   +7 more
wiley   +1 more source

Humanized VHH-hFc Fusion Proteins Targeting the L-HN Fragment of Tetanus Toxin Provided Protection In Vivo. [PDF]

Antibodies (Basel)
Li Y, Cheng K, Guo J, Jiang Y, Kang Q, Wang R, Du P, Gao C, Yu Y, Yang Z, Wang W, Lu J.   +11 more
europepmc   +1 more source